Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

NCT03878264 PHASE1 COMPLETED

This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a single oral dose of CORT118335 in healthy male participants.

Details

Lead sponsor	Corcept Therapeutics
Phase	PHASE1
Status	COMPLETED
Enrolment	12
Start date	Mon Aug 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Mar 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Healthy

Interventions

• CORT118335 Oral
• 14C-CORT118335 intravenous
• 14C-CORT118335 oral

Countries

United Kingdom